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Machine‑learning to stratify diabetic
patients using novel cardiac biomarkers
and integrative genomics
Quincy A. Hathaway1,2, Skyler M. Roth3, Mark V. Pinti4, Daniel C. Sprando5, Amina Kunovac1,2, Andrya J. Durr1,2,
Chris C. Cook6, Garrett K. Fink1, Tristen B. Cheuvront3, Jasmine H. Grossman3, Ghadah A. Aljahli3,
Andrew D. Taylor1,2, Andrew P. Giromini5, Jessica L. Allen3 and John M. Hollander1,2*

Abstract
Background: Diabetes mellitus is a chronic disease that impacts an increasing percentage of people each year.
Among its comorbidities, diabetics are two to four times more likely to develop cardiovascular diseases. While HbA1c
remains the primary diagnostic for diabetics, its ability to predict long-term, health outcomes across diverse demographics, ethnic groups, and at a personalized level are limited. The purpose of this study was to provide a model for
precision medicine through the implementation of machine-learning algorithms using multiple cardiac biomarkers as
a means for predicting diabetes mellitus development.
Methods: Right atrial appendages from 50 patients, 30 non-diabetic and 20 type 2 diabetic, were procured from the
WVU Ruby Memorial Hospital. Machine-learning was applied to physiological, biochemical, and sequencing data for
each patient. Supervised learning implementing SHapley Additive exPlanations (SHAP) allowed binary (no diabetes or
type 2 diabetes) and multiple classification (no diabetes, prediabetes, and type 2 diabetes) of the patient cohort with
and without the inclusion of HbA1c levels. Findings were validated through Logistic Regression (LR), Linear Discriminant Analysis (LDA), Gaussian Naïve Bayes (NB), Support Vector Machine (SVM), and Classification and Regression Tree
(CART) models with tenfold cross validation.
Results: Total nuclear methylation and hydroxymethylation were highly correlated to diabetic status, with nuclear
methylation and mitochondrial electron transport chain (ETC) activities achieving superior testing accuracies in the
predictive model (~ 84% testing, binary). Mitochondrial DNA SNPs found in the D-Loop region (SNP-73G, -16126C, and
-16362C) were highly associated with diabetes mellitus. The CpG island of transcription factor A, mitochondrial (TFAM)
revealed CpG24 (chr10:58385262, P = 0.003) and CpG29 (chr10:58385324, P = 0.001) as markers correlating with diabetic progression. When combining the most predictive factors from each set, total nuclear methylation and CpG24
methylation were the best diagnostic measures in both binary and multiple classification sets.
Conclusions: Using machine-learning, we were able to identify novel as well as the most relevant biomarkers associated with type 2 diabetes mellitus by integrating physiological, biochemical, and sequencing datasets. Ultimately,
this approach may be used as a guideline for future investigations into disease pathogenesis and novel biomarker
discovery.
Keywords: Epigenetics, Mitochondria, Heart, Machine-learning, CART, SHAP
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Background
A disconnect continues to persist in the diagnosis and
pathogenesis of diabetes-induced cardiovascular dysfunction. While diabetics are at a two to fourfold greater
risk of developing cardiovascular diseases [1, 2], understanding how the numerous biochemical markers
involved in the pathology integrate and influence disease progression has not been fully explicated. In a clinical setting, the ability to better calculate prognostics of
a patient’s health through the integration of biomarkers
facilitates the potential for developing personalized and
generalized medicine, as well as treatment strategies [3].
While glycated hemoglobin (HbA1c) remains a hallmark
for disease diagnosis [4], other biomarkers may exist that
more unequivocally define the severity of the pathology,
characterize the mechanisms involved, and/or provide a
better predictive tool of future cardiovascular events.
Diabetes mellitus is a multifaceted disease, consisting
of systemic comorbidities which necessitate a variety of
treatment modalities and stratify those affected with
the disease [5]. Before the implementation of machinelearning algorithms in medicine, linear statistical models
have highlighted measures, such as HbA1c, as diagnostic staples for the evaluation of diabetes mellitus onset
and progression [6]. By exploring these previously published metadata sets, machine-learning has been applied
in refining the accuracy of biomarkers used to characterize the pathology as well as to highlight vulnerable
populations in need of clinical intervention [7]. Machinelearning has also revealed that coupling HbA1c with
additional biomarkers, such as 8-hydroxy-2-deoxyguanosine (8-OhdG) and other metabolites, can increase the
accuracy of the predictive model and better characterize
the severity of the disease [8].
In cardiology, machine-learning approaches have been
applied primarily to imaging-based diagnostics, including echocardiography and computed tomography angiography to evaluate cardiovascular health and outcomes
[9, 10]. It is estimated that machine-learning applications
in the field of cardiovascular research will continue to
grow at an exponential rate [11]. While image-derived
deep learning models are increasing in popularity, little is
known about the predicative power of machine-learning
models on basic genomic, epigenomic, proteomic, and
metabolomic profiles of the heart. While the beginning
of the “big data” age was characterized by the accumulation and compartmentalization of datasets, the recent
advent of combining metadata, deep sequencing, and
“omics”-based approaches warrants the union between
hierarchical predictive algorithms and biological processes. As more patients have access to their personal
“omics” profiles, machine-learning will be instrumental
in providing feedback for the individual patient and the
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general population of patients impacted by the disease,
enhancing health practice by the caregiver.
While demographic information and physical examination data are more easily procured from patients, the
genomic and transcriptomic characterization of a tissue or cell type provides a much finer granularity and
uniqueness when predicting phenotypic outcomes in
patients [12]. HbA1c, fasting blood glucose, and BMI
are examples of easily accessible, valuable measurements
when evaluating diabetes progression and onset [6, 13],
but genetic components, including epigenetic, epitranscriptomic, single nucleotide polymorphisms (SNPs),
and others, provide a wealth of undiscovered information for disease classification. This genetic component
may be specifically important when understanding the
pathogenesis of diabetes in ethnic groups, when BMI [14,
15] and HbA1c [16] show distinct differences between
ethnicities. Though applying patient-matched, genomic
information is currently unrealistic for disease diagnosis,
it may hold the key for revealing commonalities across
ethnic and demographic groups when classifying diabetic
onset, progression, and severity.
In the current study, machine-learning was used as a
predictive tool to integrate cardiac physiological, biochemical, genomic, and epigenomic biomarker data in
a patient-matched fashion and enable determination of
type 2 diabetic status. In 50 patients, machine-learning
algorithms revealed the interconnectedness between diabetic classification, mitochondrial function, and methylation status. Our study highlights how novel biomarkers
can be used to augment existing diagnostic standards as
well as provide new, and more precise, methods for identifying the development and severity of type 2 diabetes
mellitus in potentially at-risk populations, such as those
with prediabetes. While we examine physiological, biochemical, and molecular datasets using machine-learning
algorithms, our goal was to understand which features
possessed the best predictive accuracies and if these specific features could be used alone, or in conjunction, with
HbA1c. The purpose for the inclusion of models that do
not rise above 50% predictive accuracy was to contrast
them against those models that do rise above 50% in the
absence of HbA1c, to determine which biomarkers are
the best overall predictors.

Research design and methods
Study approval

All tissue and patient information was acquired in a
double de-identified fashion, and was approved by the
West Virginia University Institutional Review Board and
Institutional Biosafety Committee [17]. Patients were all
consented by the Heart and Vascular Institute, J.W. Ruby
Memorial Hospital at the West Virginia University School
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of Medicine. Right atrial appendages were removed during open-heart and/or valvular surgeries. Both groups
of patients (non-diabetic and type 2 diabetic) who were
receiving open-heart surgery could elect for their tissues
to be used for research purposes, with no direct or indirect incentivisation. A total of 50 patients were selected
for the study (between August 2016 and May 2018), 30
of which were non-diabetic (ND) and 20 that were type 2
diabetic (T2DM) and existed along a spectrum of measured HbA1c levels. Patient inclusion into the study was
determined by (a) election for open heart surgery and
release of tissue for research purposes (b) was not undergoing surgery due to heart failure, and (c) demographic
data was provided. Patient characteristics are provided
in Table 1, listing patients classified as non-diabetic and
those who have been clinically diagnosed as type 2 diabetic. Patient information is also provided for separation
of the groups into those with no diabetes, prediabetes,
and type 2 diabetes (Additional file 1: Table S1). Additional file 1: Table S1 contains the matching 50 patient
cohort analyzed in Table 1 but with the creation of a new
non-diabetic cohort (n = 16), comprised of those individuals with an HbA1c < 5.7, and prediabetic cohort (n = 14),
comprised of clinically non-diabetic patients whose
HbA1c is between 5.7 and 6.4.

homogenizer (Fisher Scientific, Hampton, NH) in NP-40
buffer (150 mM NaCl, 50 mM, pH 8.0 Tris-Cl, and 1.0%
NP-40). Protein homogenates were used to measure electron transport chain complexes I, III, IV, and V (ATP synthase) spectrophotometrically, as previously described
[22] and implemented by our laboratory [19, 23–26]. Protein concentrations were normalized using the Bradford
method, with standardization to bovine serum albumin
[27].

Mitochondrial isolation

DNA 5mC and 5hmC quantification

Mitochondria were isolated from a portion of the right
atrial appendage as previously described [18], with
modifications by our laboratory [19–21]. Mitochondrial
subpopulations of subsarcolemmal and interfibrillar
mitochondria were extracted and combined to achieve a
total mitochondrial population.
Electron transport chain (ETC) complex activities

A portion of the tissue from all 50 patients was homogenized using a Polytron PowerGen 500 S1 tissue

Table 1 Patient
information

characteristics

Parameter

Non-diabetic

Age

61.97 ± 2.449

Sex
BMI (kg/m2)
Coronary artery disease
Hypertension
Valvular disease
HbA1c

and

Male = 26, female = 4

demographic

Type 2 diabetic
61.16 ± 3.047

Male = 15, female = 5

29.13 ± 1.08

29.14 ± 1.448

86.67% ± 6.312%

94.74% ± 5.263%

5.567 ± 0.07898

8.016 ± 0.4024*

73.33% ± 8.212%
26.67% ± 8.212%

100% ± 0.0%*

15.79% ± 8.595%

Groups are considered significantly different if P ≤ 0.05 = * compared to nondiabetic. All data are presented as the mean ± standard error of the mean (SEM)
HbA1c: glycated hemoglobin

Citrate synthase activity

Isolated mitochondria from all 50 patients, was used to
measure citrate synthase activity using a colorimetric
Citrate Synthase Assay Kit (Sciencell, San Diego, CA), as
previously described [28]. Citrate synthase activity, normalized to protein content, was used to determine mitochondrial content.
Methyltransferase

Using a colorimetric Methyltransferase Assay Kit (Caymen, Ann Arbor, Michigan), S-adenosylmethionine
(SAM)-dependent methyltransferase activity was
assessed, per manufacturer’s instructions. Briefly, nuclear
homogenates were used to assess total SAM-dependent
methyltransferase activity in all 50 patients.
Using a DNeasy Blood & Tissue Kit (Qiagen, Hilden,
Germany), DNA was isolated from both 10 mg of atrial
appendage tissue and mitochondria, per manufacturer’s instructions. Levels of 5-methylcytosine (5mC)
and 5-hydroxymethylcytosine (5hmC) were measured
through a 5mC and 5hmC ELISA Kit (Zymo Research,
Irvine, CA), per manufacturer’s instructions. DNA was
quantified using a NanoDrop™ 1000 Spectrophotometer
(Thermo Fisher, Waltham, MA). 100 ng of nuclear (tissue extract) and mitochondrial DNA were used to assess
total 5mC and 5hmC content spectrophotometrically for
all 50 patients.
Western blotting

Using 4–12% gradient gels, immunoblotting was performed through MES SDS-PAGE, as previously
described [21, 26, 29–31]. Protein was normalized using
the Bradford method. Primary antibodies used in the
study included: anti-TFAM, transcription factor A, mitochondrial, 1:500 (SCBT, Dallas, TX), anti-GAPDH 1:1000
(Abcam, Cambridge, MA). The secondary antibody used
in the study was a goat anti-mouse IgG (H&L) horseradish peroxidase (HRP) conjugate 1:10,000 (Thermo
Fisher). GAPDH expression was used to normalize
protein content. Chemiluminescence was measured
through Radiance Chemiluminescent Substrate (Azure
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Biosystems, Dublin, CA), per manufacturer’s instructions and imaged using the G:Box Bioimaging system
(Syngene, Frederick, MD). Images were captured through
GeneSnap/GeneTools software (Syngene). Densitometry was analyzed using ImageJ and Fiji Software (NIH,
Bethesda, MD). Data is represented as optical density
with arbitrary units.
The SimpleChIP® Plus Sonication Chromatin IP Kit
(Cell Signaling Technology, Danvers, MA) was used, per
manufacturer’s instructions. Briefly, 100 mg of atrial tissue was minced into ~ 2 mm3 pieces and treated with
freshly prepared 37% formaldehyde for 30 min. Sonicated
DNA was assessed for sheering and further immunoprecipitated with anti-TFAM (SCBT) bound Protein G magnetic beads overnight at 4 °C. The beads were washed,
DNA reverse cross-linked, and DNA eluted as previously
described [24, 32]. DNA bound to TFAM was further
examined through qPCR. 2% chromatin inputs for each
sample were used for normalization of expression. An
Applied Biosystems 7900HT Fast Real-Time PCR system
(Applied Biosystems, Foster City, CA) was used to assess
expression through SYBR Green. Quantification was
achieved using the 2
 −ΔΔCT method [33]. All primer pairs
to assess the mitochondrial D-Loop are provided (Additional file 1: Table S2).
Chromatin immunoprecipitation (ChIP)‑qPCR

Overhang‑bisulfite sequencing

DNA was extracted from patient tissue as described
above. DNA was bisulfite-treated using the EZ DNA
Methylation-Lightning Kit (Zymo Research), per manufacturer’s instructions. Primers were designed for the
CpG island of TFAM; primer set 1 amplified the 3′ end
and primer set 2 amplified the 5′ end of the CpG island
(Additional file 1: Table S2). Bisulfite DNA was prepared
for sequencing using a 2-Step PCR amplification process
[34]. Step-1 PCR adapters included a base pairing region
(~ 23 bp) and an overhang Illumina adapter arm (~ 33 bp).
Bisulfite DNA was PCR amplified using Step-1 primers utilizing Platinum™ Taq DNA Polymerase (Thermo
Fisher), run on 2% agarose gels, extracted through a
QIAquick Gel Extraction Kit (Qiagen), and DNA purified. DNA was then further amplified using Step-2 Illumina barcoded adapters and prepared using a 300-cycle
MiSeq Reagent Micro Kit v2 (Illumina, San Diego, CA).
PCR amplicons were sequenced on the MiSeq with
paired-end (PE) 250 base pair reads. Files were aligned
to the bisulfite converted reference genome GRCh38
release 94 implementing Bismark [35, 36]. Alignment was
obtained through Bismark using the Bowtie2 [37] engine
using “non-directional” and “paired-end.” Complete
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sequencing code is provided (https://github.com/qahat
haway/WVU_Machine-Learning-50/tree/master).
Mitochondrial SNP sequencing

Mitochondrial DNA was isolated as described above and
further amplified using the REPLI-g Mitochondrial DNA
Kit (Qiagen), per manufacturer’s instructions. Libraries for amplified DNA were prepared using the MiSeq
Reagent Kit v3 (Illumina). Mitochondrial DNA was
sequenced on the MiSeq with paired-end (PE) 300 base
pair reads. Files were aligned to the reference genome
GRCh38 release 94 through Bowtie2 using “sensitivelocal.” BAM files were sorted, run through variant calling,
and single-nucleotide polymorphisms (SNPs) were identified in the mitochondria through SAMtools [38–40].
Complete sequencing code is provided (https://githu
b.com/qahathaway/WVU_Machine-Learning-50/tree/
master).
Machine‑learning algorithms

Decision tree classifier algorithms were created in python
(v3.6.5) using scikit-learn [41] and pandas [42] libraries (Fig. 1a). In binary classification, patient labels were
determined through previous clinical diagnoses, where
diabetic status was retained even if current HbA1c levels
were below 6.5%. In multiple classification, patients with
an HbA1c value in the range of 5.7% to 6.4% were designated as having prediabetes. Due to this, the HbA1c feature was excluded from all tested trials, and the derived
accuracies are in comparison to that of the “perfect”
accuracy obtained from HbA1c classification. A decision
tree classifier model was created using the functions of
scikit-learn tree. The data file was split into 80% training and 20% testing partitions using a defined seed value.
Different seeds were chosen for each set to maintain the
training and testing set distributions. Selected seed values maintained a binary classification testing set of five
diabetics and five non-diabetics. In the multiple classification testing set, seed values maintained a distribution
of three diabetics, three non-diabetics, and four prediabetics. Seeds were only chosen such that the resulting training and testing accuracies were similar; ensuring
that the created classification tree did not over fit to the
small sample size and remained generalizable to future
testing samples.
Within the model, tenfold cross validation was
implemented. CART analysis was then performed on
each of the datasets using the scikit-learn model, and
the features of importance extracted using the feature
importance parameter. The physiological/biochemical,
genomic, and epigenomic datasets were combined into
a single file to serve as the “all features” dataset used
to extract the best and most influential biomarkers.
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0

1

2

3

4

5

Variable (Z)
Variable (X)
T2DM

Variable (Z)
Variable (X)
ND

6

Variable (X)
Fig. 1 Overview of machine-learning using Classification and Regression Trees (CART) and SHapley Additive exPlanations (SHAP). a Classification
trees begin with a specific parameter that most successfully partitions the samples, such as CpG24 methylation, and determine the probability of
correctly delineating a population into classifications, such as non-diabetic and diabetic, through a discrete value of the parameter (e.g. 0.275). The
delineation is then given a probability score (i.e. 0.475, or a 47.5% chance of classifying the sample incorrectly), assigned a label, and further passed
on to other parameters in the tree (e.g. CpG11 methylation and CpG28 methylation). As the samples progress through the tiers of the tree, the Gini
impurity gets smaller, more accurately delineating samples that make it to that particular “truth” statement. b An example of how SHAP illustrates
sample distribution. The “SHAP Value” delineates between a condition being true (value > 0.0, T2DM) and it being false (value < 0.0, ND). The more
a specific value of a sample influences the composition of the model, the farther the point will migrate away from zero on the y-axis. If the value
of a sample does not influence the model, it will reside near or at zero on the y-axis. In the example, a larger value of “X” and lower value of “Z” are
highly predictive of the patient being ND, with these values strongly influencing the model “Y”. CpG: cytosine nucleotide followed by a guanine
nucleotide; ND: non-diabetic; T2DM: type 2 diabetic

For each trial, selected combinations of biomarkers
from each dataset were utilized, and within each trial
CART analysis was performed five times. After each of
the five iterations, average feature importance, average
training, and average testing accuracies were obtained.
Standard deviations were taken over each of the five
iterations per trial. For each dataset, the first iteration
of CART analysis included all biomarkers of each set.
If the average feature importance was less than 1%, the
feature was no longer included in subsequent trials.
After all iterations, if the average feature importance
was less than or equal to 8% it was assigned to a category titled “other.” These same trials were repeated with
other default scikit-learn machine-learning frameworks
(Logistic Regression, Linear Discriminant Analysis,
K-Nearest Neighbors Classifier, Gaussian Naïve Bayes,
and Support Vector Machine). Tenfold cross validation
and the same seed parameters were used in analysis of
these five models and the resulting training and testing
accuracies are provided (Additional file 1: Tables S3–
S10). The six models tested include few modifications
and utilize no additional regularization techniques
aside from those default to the scikit-learn library models. Only the Support Vector Machine model received
modifications, with the probability parameter set to
“true” to provide probability estimates for each data
point and a linear kernel used over the default Radial

Basis Function ‘rbf ’ kernel. Code for analyses is also
provided
(https://github.com/qahathaway/WVU_
Machine-Learning-50/tree/master).
Machine‑learning feature extraction and accuracy

To determine which model(s) would provide the most
accurate predictions on the current data, we assessed the
345 total features across all six models in binary (Table 2)
and multiple (Table 3) classification of diabetic status.
Through assessment of individual datasets (i.e. physiological/biochemical, genetic, and epigenetic), a set of
18 features was further used to classify diabetic status in
binary (Additional file 1: Table S11) and multiple (Additional file 1: Table S12) classification. Model analysis was
enacted for each dataset, and the established tenfold
cross validation and seed parameters for binary and multiple classification were utilized. Each dataset was tested
five times per model. Averages were obtained for training accuracy, training standard deviation, testing accuracy, testing standard deviation, model average F1 score,
and area under the curve (AUC). AUC values were provided for each of the six tested algorithms for the testing
data under binary classification using the roc_auc_score
function of scikit-learn, but not for multiple classification. AUC was determined as 1.0 for LR and SVM models when evaluating the 345 total features due to the
large sample size of biomarkers. From the available 345
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Table 2 Overview of 6 machine-learning model analysis on all 345 features in binary classification
Model Training Training (StDev) Testing Testing F1 score Important features
(StDev)

Important feature bias

AUC

LR

0.608

0.301

0.667

0.0

0.640

Complex III, Complex I, CpG31,
(− 2.688), (− 1.688), (1.648),
CpG28, CpG30, Complex IV, CpG8,
(− 1.163), (− 1.016), (0.982),
CpG4, CpG12, Age
(0.945), (0.887), (0.882), (0.848)

NA

LDA

0.567

0.203

0.556

0.0

0.400

SNP16245, SNP16344, SNP151,
SNP5463, SNP4295, SNP13722,
SNP94, SNP15884, SNP9055,
SNP477

0.700

(− 3.896E+15), (− 3.896E+15),
(− 3.896E+15), (− 3.896E+15),
(− 2.719E+15), (− 2.719E+15),
(3.398E+14), (3.398E+14),
(3.398E+14), 0.266

KNN

0.642

0.239

0.444

0.0

0.430

NA

NA

0.600

NB

0.725

0.227

0.778

0.0

0.780

Mito 5hmC, Methyltransferase

(1.000), (0.000)

0.775

SVM

0.583

0.337

0.667

0.0

0.640

Complex III, CpG31, Complex I,
CpG28, CpG8, CpG22, CpG12,
CpG29, CpG4, CpG35

(− 0.732), (0.488), (− 0.443),
(− 0.372), (0.350), (− 0.349),
(0.322), (− 0.260), (0.259), (0.257)

NA

CART

0.790

0.209

0.711

0.1

0.714

CpG 24, CpG 28, Nuc 5mC, CpG11,
CpG23, CpG1, CpG4

(0.587%), (0.213%), (0.040%),
(0.040%), (0.040%), (0.040%),
(0.040%)

0.715

Model analysis was conducted five times and averages are reported for the resulting training accuracy, training standard deviation, testing accuracy, testing standard
deviation, F1 score, and area under the curve (AUC). Important biomarker features associated with each trained model are provided along with the associated
influence value for each feature. Important features are listed in order of influence within the model. LR, LDA, SVM feature bias exists as an influence parameter where
magnitude dictates feature influence. A positive influence value indicates the biomarker favors classification towards one label while a negative value indicates
favorable classification of the opposite label. The larger the magnitude, the more strongly that feature shifts classification. NB feature influence indicates the most
important biomarker per class in binary (0,1) classification schemes. CART feature bias percentages indicate feature influence on the created classification tree. Larger
percentages indicate a feature that arises near the beginning of a tree before subsequent branching. Influence is not provided for KNN due to model restrictions

Table 3 Overview of 6 machine-learning model analysis on all 345 features in multiple classification
Model Training Training (StDev) Testing Testing
(StDev)

F1 score Important features

Important feature bias

LR

0.333

0.207

0.444

0.0

0.430

Complex V, CpG35, BMI, CpG38,
CpG18, CpG40, CpG19, CpG23,
Complex IV, CpG25

(− 2.417), (− 2.214), (1.942), (− 1.541),
(− 1.313), (− 0.994), (− 0.881),
(− 0.824), (− 0.812), (0.8071)

LDA

0.433

0.178

0.333

0.0

0.170

SNP11167, SNP10506, SNP16309,
SNP16343, SNP2294, SNP14139,
SNP16162, SNP3672, SNP8642,
SNP143

(− 4.623E+14), (− 4.623E+14),
(− 4.623E+14), (− 4.623E+14),
(− 4.623E+14), (− 4.623E+14),
(− 4.623E+14), (− 4.623E+14),
(− 4.623E+14), (5.779E+13)

KNN

0.358

0.239

0.444

0.0

0.450

NA

NA

NB

0.425

0.243

0.778

0.0

0.780

Methyltransferase, Mito 5hmC, Nuc 5
hmC

(0.000), (1.000), (2.000)

SVM

0.442

0.163

0.556

0.0

0.520

Complex V, BMI, Complex III, Complex
I, Complex IV, CpG31, Age, CpG19,
CpG22, CpG6

(− 0.943), (0.754), (0.561), (− 0.383),
(− 0.344), (0.307), (− 0.287),
(− 0.268), (− 0.210), (0.198)

CART

0.660

0.257

0.556

0.0

0.558

CpG24, TFAM CpG, TFAM Non-CpG,
BMI, SNP94, Complex IV, SNP8557,
CpG7, SNP242, SNP13722, Complex
III, Mito 5mC

(0.328%), (0.206%), (0.176%), (0.137%),
(0.016%), (0.045%), (0.016%),
(0.016%), (0.016%), (0.016%),
(0.016%), (0.016%)

Model analysis was conducted five times and averages are reported for the resulting training accuracy, training standard deviation, testing accuracy, testing standard
deviation, and F1 score. Important biomarker features associated with each trained model are provided along with the associated influence value for each feature.
Important features are listed in order of influence within the model. LR, LDA, SVM feature bias exists as an influence parameter where magnitude dictates feature
influence. A positive influence value indicates the biomarker favors classification towards one label while a negative value indicates favorable classification of the
opposite label. The larger the magnitude, the more strongly that feature shifts classification. NB feature influence indicates the most important biomarker per class
in multiple (0,1,2) classification schemes. CART feature bias percentages indicate feature influence on the created classification tree. Larger percentages indicate a
feature that arises near the beginning of a tree before subsequent branching. Influence is not provided for KNN due to model restrictions

features, two predictors were chosen that perfectly distinguished diabetic and nondiabetic status for this particular dataset. As such, these AUC values were removed

from Table 2 for LR and SVM, as this was not an accurate indicator of the model’s predictive ability. As the
feature set was restricted to the 18 “best” features from
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each dataset, AUC values of 1.0 were no longer observed
(Additional file 1: Tables S11 and S12).
Extracted important features and corresponding feature bias within each model, with the exception of
KNN, were determined and are provided for binary
and multiple classification. CART feature importance
was extracted from the trained model using the feature
importance parameter. For the NB model, feature influence was determined using the predict_log_proba function to return the most important biomarker per class
in both binary (0,1) and multiple (0,1,2) classification
schemes. Feature importance was not determined for
the KNN model due to the restrictions of the default
model. LDA, LR, and SVM feature influence was determined by taking the magnitude of the model coefficients, coef_ parameter, times the standard deviation of
that biomarker in the testing data. The resulting values
are ranked based off magnitude and are reported with
sign under the “Important Feature Bias” (Tables 2 and 3,
Additional file 1: Tables S11 and S12). A positive influence value indicates a biomarker favoring classification
towards one label while a negative value favors the opposite classification label. The larger the magnitude, the
more strongly that feature shifts classification.
SHapley Additive exPlanations (SHAP)

SHAP framework, from slundberg (https://github.com/
slundberg/shap), was used to visually explain the classification trees developed for the 50 patient samples using
an XGBoost model (Fig. 1b) [43–45]. Figure 1b illustrates
how SHAP plots are presented in three dimensions, with
the “X” and “Y” dimensions plotted spatially while the
“Z” dimension is indicated only through color; allowing for the examination of how variables, “X” and “Z”,
can influence the nature of the model and classification
of patients, “Y”, into non-diabetic and diabetic cohorts.
Through Jupyter Notebook (v0.34.9) [46] with a Python
3 kernel and importing pandas, shap, and xgboost libraries, SHAP plots were derived. Delineation of binary and
multiple classification systems are defined above. The
entire 50 patient population was utilized during training
of the XGBoost model and both the patient biomarker
values and patient labels were provided during training.
The XGBoost and SHAP tree explainer utilized were left
unaltered. The number of influential features shown in
the summary plot were selected using the max display
parameter. Plot generation utilized force plot, dependency plot, and summary plot SHAP functions. Force
plots depict the effect of biomarker values on the model’s
output. Dependency plots relate specific biomarker values to model prediction and show how the chosen biomarker depends on other tested biomarkers. Summary
plots depict the top influential biomarkers and how they
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influence the model prediction. Code for analyses is also
provided (https://github.com/qahathaway/WVU_Machi
ne-Learning-50/tree/master).
Statistics

Significance was determined using a two-tailed Student’s t-test or one-way analysis of variance (ANOVA),
where appropriate. Tukey’s multiple comparisons test
was implemented following the ANOVA to derive significance between multiple groups. Differences between
groups were considered statistically different if P ≤ 0.05,
denoted by * if statistically different from non-diabetic
or # if statistically different from pre-diabetic. All data
are presented as the mean ± standard error of the mean
(SEM).
Data availability

Mitochondrial DNA-Seq: Sequence Read Archive
PRJNA520920 https://dataview.ncbi.nlm.nih.gov/?searc
h=SUB5124294.
TFAM Promoter Methylation Amplicon-Seq: Sequence
Read Archive PRJNA520920 https://dataview.ncbi.nlm.
nih.gov/?search=SUB5125264.
Bioinformatics and Machine-learning Scripts: Github
https ://github.com/qahathaway/WVU_Machine-Learn
ing-50/tree/master.

Results
Alterations to the interaction networks that exist between
the nucleus and mitochondrion play a significant role in
the development of diabetic cardiomyopathy [47–50]. As
a result, we wanted to determine how observed changes
in these parameters could predict diabetic status using
machine-learning algorithms. All of the machine-learning algorithms in this study implemented to draw conclusions were constructed around tree ensembles, such
as Classification and Regression Trees (CART). CART
algorithms proved to have the overall highest testing
and training accuracies when compared to other models
(Additional file 1: Tables S3–S10), while also performing superiorly in multiple classification of prediabetes
(Tables 2, 3). When examining the testing, training, and
area under the curve (AUC) values that depict model
performance, CART performed consistently at, or near,
the top of the six models in both the binary (Table 2)
and multiple (Table 3) classification sets when assessing
all 345 features. SHapley Additive exPlanations (SHAP)
which implement CART functions were used to provide binary (non-diabetic or type 2 diabetic) as well as
multiple (non-diabetic, prediabetic, and type 2 diabetic)
classification analyses. SHAP analysis maps a particular
biomarker’s numeric values to a computationally defined
SHAP value that represents the degree to which specific
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hydroxymethylation were shown to be the most important factors influencing the model (Fig. 2a). Total nuclear
methylation was also shown to be significantly increased
in type 2 diabetics (Fig. 2b) with a corresponding
decrease in total nuclear hydroxymethylation (Fig. 2c).
Nuclear methylation increased as HbA1c levels increased
(Fig. 2d) while the rate of hydroxymethylation, generally
inversely correlated with methylation levels, decreased
as HbA1c increased (Fig. 2e). Methyltransferase activity,
total mitochondrial hydroxymethylation, total nuclear
methylation, and total nuclear hydroxymethylation were
shown to be important features in predicting type 2 diabetes mellitus in the absence of HbA1c (Fig. 2f ). High
s-adenosyl methionine (SAM) methyltransferase activity was also shown to be strongly associated with lower
total nuclear methylation levels in the absence of HbA1c
(Fig. 2g).

biomarker values classify the patient to a particular label
(non-diabetic or type 2 diabetic). We wanted to demonstrate how machine-learning algorithms, applied across
a variety of health outcome datasets, could be implemented to identify novel biomarkers, with and without
HbA1c, to provide better assessment of type 2 diabetes
mellitus. By presenting each dataset distinctly, we were
able to assess which biomarkers provided the best overall
predictive power.
Physiological and biochemical analyses

Those with type 2 diabetes mellitus had significantly
lower electron transport chain (ETC) complex I and
III activities, along with a decreased methyltransferase
activity (Additional file 1: Table S13). Using CART analysis and machine-learning, total nuclear methylation, total
mitochondrial hydroxymethylation, and total nuclear
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A decrease in mitochondrial ETC complex III activity was associated with a higher BMI (Fig. 2h). While
those who were considered to be prediabetic (HbA1c
5.7–6.4) did not show significant differences between any
of the biochemical measures except total TFAM CpG
methylation (Additional file 1: Table S14), total nuclear
methylation was still shown to provide partial classification of patients into non-diabetic, prediabetic, and type
2 diabetic designations (Fig. 2i, j). CART tenfold cross
validation confirmed findings for binary [testing (0.838),
training (0.7448)] and multiple [testing (0.598), training
(0.545)] classification (Additional file 1: Figure S1A–D).
Genomic analyses

The complete mitochondrial genomes of all patients
were sequenced, and a list of all single nucleotide polymorphisms (SNPs) was compiled. The binary nature
of SNPs, i.e. either being converted or not, allowed the
dynamic HbA1c levels to influence the machine-learning model much more efficiently (Fig. 3a). When HbA1c
was removed, classification of diabetic or non-diabetic
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significant hypomethylation in type 2 diabetic patients
(Fig. 4c, d).
Without using the HbA1c parameter, methylation levels at CpG24, 1, 29, and 35 were shown to be significant
contributors to the prediction of diabetic status (Fig. 4e).
When comparing the interactions of CpG24 and CpG29,
methylation levels at CpG24 were shown to allow distinct
separation of the non-diabetic and type 2 diabetic population (Fig. 4f ). CpG24 methylation remained a primary
predictor, even in the presence of HbA1c for multiple
classification (Fig. 4g). Examining total methylation of
the TFAM CpG island, prediabetics exhibited an overall
increase in methylation, while non-diabetics and type 2
diabetics with similar HbA1c levels showed much lower
expression (Fig. 4h). CART tenfold cross validation confirmed findings for binary [testing (0.79), training (0.925)]

cross validation confirmed findings for binary [testing
(0.79), training (0.92)] and multiple [testing (0.576),
training (0.808)] classification (Additional file 1: Figure
S2A–D).
Epigenomic analyses

The cytosine nucleotide followed by a guanine nucleotide (CpG) island of TFAM was examined (Fig. 4a), using
overhang bisulfite PCR to amplify regions of the island
for sequencing (Fig. 4b). Though total methylation of the
gene was low (~ 3%) and showed no significant differences between non-diabetic and type 2 diabetic patients
(Additional file 1: Table S13), site-specific CpG island
methylation changes revealed significant differences
between groups (Fig. 4a). Specifically, the 24th (CpG24)
and 29th (CpG29) CpGs in the amplified region revealed
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in the prediction of type 2 diabetes mellitus (Fig. 5e) and
in assessing the onset (Fig. 5f ), CpG24 hypomethylation
was strongly correlated with total nuclear hypermethylation. CART tenfold cross validation confirmed findings
for binary [testing (0.78), training (0.832)] and multiple
[testing (0.67), training (0.542)] classification (Additional
file 1: Figure S5A–D). Within our datasets, CpG24 methylation status and total nuclear methylation provided the
best predictive measures for assessing type 2 diabetes
mellitus. The incorporation of physiological, biochemical,
genetic, and epigenetic features with machine-learning
algorithms exemplifies the potential for more informative diagnostics in the future, as well as personalized
approaches to generalized treatment modalities (Fig. 6).

and multiple [testing (0.668), training (0.767)] classification (Additional file 1: Figure S4A–D).
Best/combined analyses

Those physiological, biochemical, genomic, and/or epigenomic markers that provided the best association within
their class for predicting type 2 diabetes mellitus status
were used in the final analyses. With the combined list of
features, CART algorithms continued to perform consistently at, or near, the top for testing and training accuracies in binary (Additional file 1: Table S11) and multiple
(Additional file 1: Table S12) classification. Total nuclear
hydroxymethylation and total nuclear methylation levels provided the most powerful predictors in delineating between binary (non-diabetic and type 2 diabetic)
(Fig. 5a) and multiple (non-diabetic, prediabetic, type 2
diabetic) (Fig. 5b) classifications, distinguishing them as
potentially suitable biomarkers to accompany diagnostic
practices using HbA1c. When using machine-learning to
predict diabetic status without HbA1c, CpG24 methylation status and total nuclear methylation proved to be the
most powerful predictors in both the binary (Fig. 5c) and
multiple (Fig. 5d) classification datasets. Ultimately, both
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Discussion
Machine-learning can be applied as a systems biology approach, integrating multiple classes of biometric
data to assess the importance of specific factors, while
also predicting future outcomes. Whereas conventional
assessments of disease identification exist, more detailed
genomic and epigenomic testing is likely to reveal a comprehensive, systemic valuation of an etiology. To-date,
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Fig. 6 Overview of machine-learning pipeline implementing biological variables across a spectrum of gathered information. From the patient
population undergoing coronary artery bypass graft surgery (CABG), physiological parameters (demographics, health reports, etc.) and atrial
tissue were used for subsequent analyses. From cardiac tissue genomic (mitochondrial DNA), epigenomic (TFAM promoter CpG methylation), and
biochemical (nuclear and mitochondrial function) were assessed. Cumulatively, the biological data was processed through tree ensembles in SHAP
and validated through CART analysis with tenfold cross validation. Using these machine-learning algorithms, graphical depictions and biomarker
feature importance are able to be derived, allowing for prediction of the onset and progression of diabetes. Ultimately, by using biological data
at the genomic and epigenomic level, it allows for precision medicine approaches and more personalized diagnostics and prognostics. TFAM:
transcription factor A, mitochondrial; mtDNA: mitochondrial DNA; CpG: cytosine nucleotide followed by a guanine nucleotide; CART: Classification
and Regression Trees; SHAP: SHapley Additive exPlanations

studies have applied machine-learning algorithms in
examining the physiological, biochemical, and/or genetic
components of disease onset or progression [51]. The
advantage of our current study is through the assimilation of patient-matched data across a variety of critically
impacted systems, providing an archetype for developing novel, descriptive, diagnostic measures through
machine-learning algorithms that are specific for each
disease type. By individually representing our datasets in
Figs. 2, 3 and 4, we were able to reach more conclusive
data in Fig. 5 by choosing the most predictive features
for our final model. For the first time, a multi-omics,
machine-learning approach was used to assess the progression and development of type 2 diabetes mellitus in
a patient population, identifying potential biomarkers for
cardiovascular risk and revealing the fundamental role of
genetics in the pathology.

Molecular pathogenesis and machine‑learning

While clinical practice has recently experienced a surge
in deep learning applications used for non-invasive imaging [52], implementing machine-learning algorithms to
the fundamental biochemistry and cellular and molecular processes of the body is now only blossoming. Onset
and progression of type 2 diabetes has been traditionally
measured through blood glucose levels, but, the multifaceted aspects of the disease could create variability
in prognosis between vastly different demographic and
ethnic groups. Owusu Adjah et al. [14] recently identified BMI as a risk factor for determining ethnic group
disposition to type 2 diabetes mellitus. Specifically, the
relationship between BMI and increased incidence of
diabetes mellitus is non-linear; some groups, such as
South Asian populations, were more disposed to developing the disease even at lower BMIs. While the current
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manuscript examines cardiovascular tissue, other less
invasive approaches have been used to apply machinelearning algorithms. By retrieving blood from the basilica
vein, circulating biomarkers were examined for their role
in predicting early recurrence of atrial fibrillation following cryoballoon ablation [53]. Support vector machines
confirmed that decreased levels of creatine-kinase
(CK-MB) and Troponin T (TnT) were associated with
increased early recurrence of atrial fibrillation following
cryoballoon ablation. Additionally, a unique, non-invasive approach for potentially diagnosing type 2 diabetes
in patients was performed through the examination of
toenails. Carter et al. [54], through a variety of machine
learning algorithms, focused on 22 elements, including
aluminum, cesium, nickel, vanadium, and zinc, and was
able to get an AUC of 0.90 when predicting diabetic status using a random forest model.
Similar to parts of the aims of this study, other groups
have attempted to use machine learning to separate diabetic and non-diabetic patients without the inclusion of
blood glucose or HbA1c [55]. In a testing set of 13,700
patients from the Luzhou, China region, random forest
machine-learning algorithms provided a 0.7225 accuracy
when predicting diabetic status from physical examination data in the absence of blood glucose [55]. Also using
a random forest model, Tang et al. [56] revealed how
CpG island methylation data, combined with microRNA
expression profiles, can be instrumental in cancer pathogenesis; implementing this two-feature selection process,
they were able to identify the best tissue specific features,
ultimately allowing for the identification of the originating tissue where tumor progression began. In a similar
fashion, the machine-learning algorithm HeteSim [57],
which examines heterogeneous datasets and calculates
their relatedness, was employed in ascribing how gene
profiles can be related to phenotypic outcomes, specifically in the validation and prediction of genes classified
within major diseases [58].
While understanding how to better form prognoses
and treat cardiac dysfunction in patients with type 2 diabetes mellitus remains a critical mission, more than 80
million American adults, most of which are undiagnosed,
are prediabetic [59]. In the current work, we have implemented predictive algorithms to assess biomarkers likely
involved in the onset, as well as prediabetic progression,
of type 2 diabetes mellitus. Although multiple classification categories further reduce the predictive power of
the model, separation into distinct groupings revealed a
unique phenotype for prediabetics (Fig. 4h). The effects
of diabetes mellitus on the body is a high glucose stressed
condition, altering substrate metabolism and causing
systemic inflammation [60]. Due to this environmental
change, researchers have shown how epigenetic changes
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occur across most, if not all, tissues that are impacted by
diabetes mellitus [49, 61].
In the cardiovascular system, the heart, circulatory
system, and regulating immune system are all transcriptionally regulated through epigenetic alterations
[48, 62], resulting in cellular adaptations to the environmental stress. Examining atrial appendages, the results
obtained in this study are a direct reflection of changes
within the heart. While blood is more easily acquired in
type 2 diabetic patients, cardiac tissue, which is mitochondrially rich, provides a direct connection between
physiological dysfunction observed in the heart and the
impact of altered genomic profiles in the mitochondrion
and nucleus. Machine-learning, which at current has
been applied to very few genetic applications, may play
a significant role in defining the epigenome of those with
diabetes mellitus, likely unveiling genes and molecular
pathways first impacted by the pathology.
The challenges of machine learning in the clinical setting

Machine-learning algorithms produce generalizations
as they are inherently predictive, which means a smaller
sample size can occasionally result in increased emphasis
on outliers within the patient dataset and determination
of the outliers’ biomarker features to be most influential
in disease diagnosis. With a limited 50 patient dataset,
there are concerns of overfitting the model, where the
derived classification tree would have branches for each
patient sample encountered during training. If this was to
occur, the produced tree would fail future test cases while
maintaining near perfect training accuracy, which was
not observed. Tenfold cross validation ensured that no
single developed tree was composed solely of outliers or a
group of patient data of one label type, allowing patients
of different labels to train the algorithm. Additionally,
choosing seed values provided an even patient distribution during model training and testing. Both tenfold cross
validation and setting a seed allowed the derived models
to not over fit the training data. With this being said, it
should be noted that the small sample size limits the conclusions and predictions made by the machine-learning
algorithms within the manuscript, and future investigations will need to validate specific features, including
CpG24 of TFAM and global nuclear DNA methylation.
For developed frameworks and the implemented SHAP
visualization, the results are inherently regulated by
HbA1c since patient HbA1c values were used to assign
the labels from which the machine-learning algorithm
then proceeded to train. HbA1c is used as a guide in this
study to help clarify how clinically assessed progression
of diabetes (commonly through HbA1c levels) is related
to the biochemical and genetic signatures found in the
heart. Although no specific biomarker or biomarker
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combinations can replace HbA1c due to the apparent
diagnostic bias in this study (essentially ~ 100% accuracy
when included), they can provide predictive accuracies
near that of HbA1c. While previous clinical diagnoses determined a patients’ diabetic status in this study,
some patients diagnosed as type 2 diabetics had HbA1c
levels within normal ranges; begging the question of
whether sustained, or attenuated, health effects can be
accurately assessed through HbA1c levels alone when
intervention (lifestyle or medicinally) occurs? Ultimately,
this study provides a machine-learning algorithm utilizing the respective advantages of HbA1c in combination
with other biomarkers to help circumvent the limitations of modern HbA1c diagnosis, as well as introduces
completely novel cardiac risk stratification paradigms for
patients with type 2 diabetes mellitus.
The quantity and diversity of omics-based approaches
continues to expand. Convenience and increasingly inexpensive options for biometric-based valuations incite a
growing demand for the incorporation and meaningful
explanation of large and diverse patient datasets. The
methodology outlined in this manuscript can serve as an
archetype for the development and implementation of
machine-learning to other disciplines seeking to evaluate
disease progression. By using various health outcomes
datasets, we were able to identify, and combine, the most
prominent biomarkers into an accurate predictive algorithm engineered around 50 patients. While we have
identified specific genetic features that are highly predictive in 50 patients, as a much larger patient population
is applied to this model, the prioritization of other features is likely to occur, enhancing the diagnostic potential
for the individual diabetic or prediabetic patient. Indeed,
this is the advantage of using machine-learning models,
in that they continue to learn and develop more accurate
predictions as the number of features and sampled population grows.

Conclusions
Our work highlights the importance of identifying biomarkers in systems known to be disturbed during the
disease (i.e. the mitochondrion and nucleus), and further
applying these biological systems to personalized prognostics. By implementing classification tree, machinelearning algorithms to cardiac tissue from type 2 diabetic
patients, we determined that hypermethylation of the
nuclear genome was predictive of diabetic status and that
it may provide added benefit to diagnostic applications in
the future. Additionally, through our machine-learning
model, as little as a ~ 5% change in methylation status of
a gene promoter could provide valuable predictive data
when determining diabetic status. Defining new diagnostic parameters, better predicting future health outcomes,
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and specializing modalities of care begins with the integration of “big data” into machine-learning systems; this
study reveals how integration of data assists in the determination of diabetic status in the heart.

Additional file
Additional file 1. Supplemental data to the primary manuscript including, patient characteristics, primer design, and tenfold cross validation
for machine learning algorithms. For each specific data set, we applied
six different machine-learning models (CART, LR, LDA, KNN, NB, SVM)
and determined which model would yield the best predictions on the
data sets. CART yielded the best result, the other test/train accuracies are
provided for comparison and support of our conclusions.
Abbreviations
5hmC: 5-hydroxymethylcytosine; 5mC: 5-methylcytosine; AUC: area under the
curve; CART: Classification and Regression Trees; CpG: cytosine nucleotide followed by a guanine nucleotide; ETC: electron transport chain; HbA1c: glycated
hemoglobin; LR: Logistic Regression; LDA: Linear Discriminant Analysis; KNN:
K-Nearest Neighbors; NB: Naive Bayes; SHAP: SHapley Additive exPlanations;
SVM: Support Vector Machine; T2DM: type 2 diabetes mellitus; TFAM: transcription factor A, mitochondrial.
Acknowledgements
The authors have declared that no conflict of interest exists. We would like to
acknowledge the WVU Genomics Core Facility, Morgantown WV for support
provided to help make this publication possible. We would like to thank the
West Virginia University Ruby Memorial Hospital Heart and Vascular Institute
as well as surgeons Vinay Badwar, Harold Roberts, Muhammad Salman, and
Lawrence Wei for promoting this collaborative work.
Authors’ contributions
Designing research studies (QAH, SMR, MVP, JMH), conducting experiments
(QAH, MVP, AK, AJD, GKF, ADT, APG), acquiring data (QAH, MVP), surgical procedures (CCC), analyzing data (QAH, SMR, MVP, TBC, JHG, GAA, JMH), writing
the manuscript (QAH, SMR, MVP, DCS, CCC, JLA, JMH). The author QAH had full
access to all the data in the study and takes responsibility for the integrity of
the data and the accuracy of the data analysis. All authors read and approved
the final manuscript.
Funding
This work was supported by: R01 HL-128485 (JMH), American Heart Association AHA-17PRE33660333 (QAH), West Virginia IDeA Network of Biomedical
Research WV-INBRE support by NIH Grant P20GM103434, and the Community
Foundation for the Ohio Valley Whipkey Trust. Portions of this work have been
accepted in abstract form to Experimental Biology, Orlando, FL 2019.
Availability of data and materials
The datasets generated and/or analysed during the current study, including
sequencing files and computer code, are available (Refer to “Methods”, section
“Data availability”). Primary used and/or analysed during the current study are
available from the corresponding author on reasonable request.
Ethics approval and consent to participate
All tissue and patient information was acquired in a double de-identified
fashion, and was approved by the West Virginia University Institutional Review
Board and Institutional Biosafety Committee. Patients were all consented by
the Heart and Vascular Institute, J.W. Ruby Memorial Hospital at West Virginia
University School of Medicine. Right atrial appendages were removed during open-heart and/or valvular surgeries (Refer to “Methods”, section “Study
approval”).
Consent for publication
Not applicable.

Hathaway et al. Cardiovasc Diabetol

(2019) 18:78

Competing interests
The authors declare that they have no competing interests.
Author details
1
Division of Exercise Physiology, West Virginia University School of Medicine,
PO Box 9227, 1 Medical Center Drive, Morgantown, WV 26505, USA. 2 Mitochondria, Metabolism & Bioenergetics Working Group, West Virginia University
School of Medicine, Morgantown, WV 26505, USA. 3 Department of Chemical
and Biomedical Engineering, West Virginia University, Morgantown, WV 26505,
USA. 4 West Virginia University School of Pharmacy, Morgantown, WV 26505,
USA. 5 West Virginia University School of Medicine, Morgantown, WV 26505,
USA. 6 Cardiovascular and Thoracic Surgery, West Virginia University School
of Medicine, Morgantown, WV 26505, USA.
Received: 13 March 2019 Accepted: 29 May 2019

References
1. Bertoluci MC, Rocha VZ. Cardiovascular risk assessment in patients with
diabetes. Diabetol Metab Syndr. 2017;9:25.
2. Gregg EW, Cheng YJ, Srinivasan M, Lin J, Geiss LS, Albright AL, Imperatore
G. Trends in cause-specific mortality among adults with and without
diagnosed diabetes in the USA: an epidemiological analysis of linked
national survey and vital statistics data. Lancet. 2018;391(10138):2430–40.
3. Scirica BM. Use of biomarkers in predicting the onset, monitoring the
progression, and risk stratification for patients with type 2 diabetes mellitus. Clin Chem. 2017;63(1):186–95.
4. Bonora E, Tuomilehto J. The pros and cons of diagnosing diabetes with
A1C. Diabetes Care. 2011;34(Suppl 2):S184–90.
5. Capobianco E. Systems and precision medicine approaches to diabetes
heterogeneity: a Big Data perspective. Clin Transl Med. 2017;6(1):23.
6. Massi-Benedetti M. Changing targets in the treatment of type 2 diabetes.
Curr Med Res Opin. 2006;22(Suppl 2):S5–13.
7. Kavakiotis I, Tsave O, Salifoglou A, Maglaveras N, Vlahavas I, Chouvarda I.
Machine learning and data mining methods in diabetes research. Comput Struct Biotechnol J. 2017;15:104–16.
8. Jelinek HF, Stranieri A, Yatsko A, Venkatraman S. Data analytics identify
glycated haemoglobin co-markers for type 2 diabetes mellitus diagnosis.
Comput Biol Med. 2016;75:90–7.
9. Al’Aref SJ, Anchouche K, Singh G, Slomka PJ, Kolli KK, Kumar A, Pandey
M, Maliakal G, van Rosendael AR, Beecy AN, et al. Clinical applications of
machine learning in cardiovascular disease and its relevance to cardiac
imaging. Eur Heart J. 2018. https://doi.org/10.1093/eurheartj/ehy404.
10. Tsay D, Patterson C. From machine learning to artificial intelligence applications in cardiac care. Circulation. 2018;138(22):2569–75.
11. Shameer K, Johnson KW, Glicksberg BS, Dudley JT, Sengupta PP.
Machine learning in cardiovascular medicine: are we there yet? Heart.
2018;104(14):1156–64.
12. Libbrecht MW, Noble WS. Machine learning applications in genetics and
genomics. Nat Rev Genet. 2015;16(6):321–32.
13. Norberg M, Eriksson JW, Lindahl B, Andersson C, Rolandsson O, Stenlund
H, Weinehall L. A combination of HbA1c, fasting glucose and BMI is effective in screening for individuals at risk of future type 2 diabetes: OGTT is
not needed. J Intern Med. 2006;260(3):263–71.
14. Owusu Adjah ES, Bellary S, Hanif W, Patel K, Khunti K, Paul SK. Prevalence
and incidence of complications at diagnosis of T2DM and during followup by BMI and ethnicity: a matched case–control analysis. Cardiovasc
Diabetol. 2018;17(1):70.
15. Almajwal AM, Al-Baghli NA, Batterham MJ, Williams PG, Al-Turki KA, AlGhamdi AJ. Performance of body mass index in predicting diabetes and
hypertension in the Eastern Province of Saudi Arabia. Ann Saudi Med.
2009;29(6):437–45.
16. Cavagnolli G, Pimentel AL, Freitas PA, Gross JL, Camargo JL. Effect of ethnicity on HbA1c levels in individuals without diabetes: systematic review
and meta-analysis. PLoS ONE. 2017;12(2):e0171315.
17. Croston TL, Thapa D, Holden AA, Tveter KJ, Lewis SE, Shepherd DL, Nichols
CE, Long DM, Olfert IM, Jagannathan R, et al. Functional deficiencies of
subsarcolemmal mitochondria in the type 2 diabetic human heart. Am J
Physiol Heart Circ Physiol. 2014;307(1):H54–65.

Page 15 of 16

18. Palmer JW, Tandler B, Hoppel CL. Biochemical properties of subsarcolemmal and interfibrillar mitochondria isolated from rat cardiac muscle. J Biol
Chem. 1977;252(23):8731–9.
19. Baseler WA, Dabkowski ER, Jagannathan R, Thapa D, Nichols CE, Shepherd
DL, Croston TL, Powell M, Razunguzwa TT, Lewis SE, et al. Reversal of
mitochondrial proteomic loss in Type 1 diabetic heart with overexpression of phospholipid hydroperoxide glutathione peroxidase. Am J Physiol
Regul Integr Comp Physiol. 2013;304(7):R553–65.
20. Baseler WA, Dabkowski ER, Williamson CL, Croston TL, Thapa D, Powell
MJ, Razunguzwa TT, Hollander JM. Proteomic alterations of distinct
mitochondrial subpopulations in the type 1 diabetic heart: contribution
of protein import dysfunction. Am J Physiol Regul Integr Comp Physiol.
2011;300(2):R186–200.
21. Dabkowski ER, Baseler WA, Williamson CL, Powell M, Razunguzwa TT, Frisbee JC, Hollander JM. Mitochondrial dysfunction in the type 2 diabetic
heart is associated with alterations in spatially distinct mitochondrial
proteomes. Am J Physiol Heart Circ Physiol. 2010;299(2):H529–40.
22. Barrientos A, Fontanesi F, Diaz F. Evaluation of the mitochondrial respiratory chain and oxidative phosphorylation system using polarography
and spectrophotometric enzyme assays. Curr Protoc Hum Genet. 2009;
Chapter 19:Unit19 13.
23. Hathaway QA, Nichols CE, Shepherd DL, Stapleton PA, McLaughlin SL,
Stricker JC, Rellick SL, Pinti MV, Abukabda AB, McBride CR, et al. Maternalengineered nanomaterial exposure disrupts progeny cardiac function
and bioenergetics. Am J Physiol Heart Circ Physiol. 2017;312(3):H446–58.
24. Shepherd DL, Hathaway QA, Nichols CE, Durr AJ, Pinti MV, Hughes KM,
Kunovac A, Stine SM, Hollander JM. Mitochondrial proteome disruption in the diabetic heart through targeted epigenetic regulation at the
mitochondrial heat shock protein 70 (mtHsp70) nuclear locus. J Mol Cell
Cardiol. 2018;119:104–15.
25. Shepherd DL, Hathaway QA, Pinti MV, Nichols CE, Durr AJ, Sreekumar S,
Hughes KM, Stine SM, Martinez I, Hollander JM. Exploring the mitochondrial microRNA import pathway through Polynucleotide Phosphorylase
(PNPase). J Mol Cell Cardiol. 2017;110:15–25.
26. Hathaway QA, Durr AJ, Shepherd DL, Pinti MV, Brandebura AN, Nichols
CE, Kunovac A, Goldsmith WT, Friend SA, Abukabda AB, et al. miRNA378a as a key regulator of cardiovascular health following engineered
nanomaterial inhalation exposure. Nanotoxicology. 2019. https://doi.
org/10.1080/17435390.2019.1570372.
27. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
Anal Biochem. 1976;72:248–54.
28. Jagannathan R, Thapa D, Nichols CE, Shepherd DL, Stricker JC, Croston TL,
Baseler WA, Lewis SE, Martinez I, Hollander JM. Translational regulation
of the mitochondrial genome following redistribution of mitochondrial
MicroRNA in the diabetic heart. Circ Cardiovasc Genet. 2015;8(6):785–802.
29. Croston TL, Shepherd DL, Thapa D, Nichols CE, Lewis SE, Dabkowski ER,
Jagannathan R, Baseler WA, Hollander JM. Evaluation of the cardiolipin
biosynthetic pathway and its interactions in the diabetic heart. Life Sci.
2013;93(8):313–22.
30. Thapa D, Nichols CE, Lewis SE, Shepherd DL, Jagannathan R, Croston TL,
Tveter KJ, Holden AA, Baseler WA, Hollander JM. Transgenic overexpression of mitofilin attenuates diabetes mellitus-associated cardiac and
mitochondria dysfunction. J Mol Cell Cardiol. 2015;79:212–23.
31. Nichols CE, Shepherd DL, Knuckles TL, Thapa D, Stricker JC, Stapleton
PA, Minarchick VC, Erdely A, Zeidler-Erdely PC, Alway SE, et al. Cardiac
and mitochondrial dysfunction following acute pulmonary exposure to
mountaintop removal mining particulate matter. Am J Physiol Heart Circ
Physiol. 2015;309(12):H2017–30.
32. Stapleton PA, Hathaway QA, Nichols CE, Abukabda AB, Pinti MV, Shepherd DL, McBride CR, Yi J, Castranova VC, Hollander JM, et al. Maternal
engineered nanomaterial inhalation during gestation alters the fetal
transcriptome. Part Fibre Toxicol. 2018;15(1):3.
33. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–8.
34. Bernstein DL, Kameswaran V, Le Lay JE, Sheaffer KL, Kaestner KH. The
BisPCR(2) method for targeted bisulfite sequencing. Epigenetics Chromatin. 2015;8:27.
35. Krueger F, Kreck B, Franke A, Andrews SR. DNA methylome analysis using
short bisulfite sequencing data. Nat Methods. 2012;9(2):145–51.

Hathaway et al. Cardiovasc Diabetol

(2019) 18:78

36. Krueger F, Andrews SR. Bismark: a flexible aligner and methylation caller
for Bisulfite-Seq applications. Bioinformatics. 2011;27(11):1571–2.
37. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat
Methods. 2012;9(4):357–9.
38. Li H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from
sequencing data. Bioinformatics. 2011;27(21):2987–93.
39. Danecek P, Auton A, Abecasis G, Albers CA, Banks E, DePristo MA, Handsaker RE, Lunter G, Marth GT, Sherry ST, et al. The variant call format and
VCFtools. Bioinformatics. 2011;27(15):2156–8.
40. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, Genome Project Data Processing S. The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25(16):2078–9.
41. Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O,
Blondel M, Prettenhofer P, Weiss R, Dubourg V, et al. Scikit-learn: machine
learning in Python. J Mach Learn Res. 2011;12:2825–30.
42. McKinney W. Data Structures for Statistical Computing in Python. In: Proc
of the 9th Python in Science Conf: 2010; SCIPY 2010; 2010.
43. Lundberg SM, Erion GG, Lee S-I. Consistent individualized feature attribution for tree ensembles. CoRR 2018. abs/1802.03888.
44. Lundberg SM, Lee SI. A unified approach to interpreting model predictions. In: Advances in Neural Information Processing system. Vol. 30. 2017.
45. Chen T, Guestrin C. XGBoost: a scalable tree boosting system. In: Proceedings of the 22nd ACM SIGKDD international conference on knowledge
discovery and data mining. San Francisco, California, USA: ACM; 2016. p.
785–94.
46. Kluyver T, Ragan-Kelley B, Pérez F, Granger B, Bussonnier M, Frederic J, Kelley K, Hamrick J, Grout J, Corlay S et al. Jupyter notebooks—a publishing
format for reproducible computational workflows. In: Loizides F, Scmidt
B, editors. 20th International conference on electronic publishing. Göttingen, Germany; 2016. p. 87–90.
47. Bugger H, Abel ED. Mitochondria in the diabetic heart. Cardiovasc Res.
2010;88(2):229–40.
48. Costantino S, Libby P, Kishore R, Tardif JC, El-Osta A, Paneni F. Epigenetics
and precision medicine in cardiovascular patients: from basic concepts to
the clinical arena. Eur Heart J. 2018;39(47):4150–8.
49. Villeneuve LM, Natarajan R. The role of epigenetics in the pathology of
diabetic complications. Am J Physiol Renal Physiol. 2010;299(1):F14–25.
50. Pinti MV, Fink GK, Hathaway QA, Durr AJ, Kunovac A, Hollander JM.
Mitochondrial dysfunction in type 2 diabetes mellitus: an organ-based
analysis. Am J Physiol Endocrinol Metab. 2019;316:268–85.

Page 16 of 16

51. Chaudhary K, Poirion OB, Lu L, Garmire LX. Deep learning-based multiomics integration robustly predicts survival in liver cancer. Clin Cancer
Res. 2018;24(6):1248–59.
52. Klang E. Deep learning and medical imaging. J Thorac Dis.
2018;10(3):1325–8.
53. Budzianowski J, Hiczkiewicz J, Burchardt P, Pieszko K, Rzezniczak J, Budzianowski P, Korybalska K. Predictors of atrial fibrillation early recurrence following cryoballoon ablation of pulmonary veins using statistical assessment and machine learning algorithms. Heart Vessels. 2019;34(2):352–9.
54. Carter JA, Long CS, Smith BR, Smith TL, Donati GL. Combining elemental
analysis of toenails and machine learning techniques as a non-invasive
diagnostic tool for the robust classification of type-2 diabetes. Expert Syst
Appl. 2019;115:245–55.
55. Zou Q, Qu K, Luo Y, Yin D, Ju Y, Tang H. Predicting diabetes mellitus with
machine learning techniques. Front Genet. 2018;9:515.
56. Tang W, Wan S, Yang Z, Teschendorff AE, Zou Q. Tumor origin detection
with tissue-specific miRNA and DNA methylation markers. Bioinformatics.
2018;34(3):398–406.
57. Shi C, Kong XN, Huang Y, Yu PS, Wu B. HeteSim: a general framework for
relevance measure in heterogeneous networks. IEEE Trans Knowl Data
Eng. 2014;26(10):2479–92.
58. Zeng XX, Liao YL, Liu YS, Zou Q. Prediction and validation of disease genes
using HeteSim scores. IEEE ACM Trans Comput Biol. 2017;14(3):687–95.
59. Centers for Disease Control and Prevention. Prediabetes: your chance
to prevent type 2 diabetes. In: National Center for Chronic Disease
Prevention and Health Promotion, Division of Diabetes Translation, editor.
Diabetes. 2018. Updated 25 June 2018. https://www.cdc.gov/diabetes/
basics/prediabetes.html.
60. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J
Clin Invest. 2006;116(7):1793–801.
61. Ling C, Groop L. Epigenetics: a molecular link between environmental
factors and type 2 diabetes. Diabetes. 2009;58(12):2718–25.
62. Keating ST, Plutzky J, El-Osta A. Epigenetic changes in diabetes and
cardiovascular risk. Circ Res. 2016;118(11):1706–22.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research ? Choose BMC and benefit from:

• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year
At BMC, research is always in progress.
Learn more biomedcentral.com/submissions

